Revenue by Segment:

• Pharmaceutical Active Ingredients (APIs): 60%
• Finished Products (Drug Products): 40%

TOP 3 Markets:

• USA: 35%
• Europe (excluding Switzerland): 30%
• Switzerland: 15%

Siegfried Holding AG generates the majority of its revenue from the production of pharmaceutical active ingredients and finished products. The US market accounts for the largest share of revenue, followed by Europe and Switzerland. These markets are crucial for the company as they are characterized by both high demand and strategic partnerships.

Production sites of Siegfried Holding AG:

1. Zofingen, Switzerland
2. Pennsville, USA
3. Irvine, USA
4. Evionnaz, Switzerland
5. St. Vulbas, France
6. Minden, Germany
7. Hamelin, Germany
8. Barcelona, Spain
9. Malta

Siegfried Holding AG operates several production sites worldwide. These sites are strategically located in Europe and the USA to ensure efficient production and delivery of pharmaceutical active ingredients and products. The sites in Switzerland, the USA, and Europe enable the company to flexibly respond to different markets and ensure high quality in production.

Revenue Growth: Estimated 8-10% annually (2025)

Focus on Innovation and Expansion:

Siegfried Holding AG pursues a growth strategy that is strongly focused on innovation and geographical expansion. The company continuously invests in research and development to expand its product range and tap into new markets.

Another key focus is on strategic partnerships and acquisitions to increase production capacities and strengthen global presence. These measures are intended to further enhance the market position in the pharmaceutical industry and ensure long-term stable growth rates.

In addition, Siegfried is committed to sustainable practices and digitalization to achieve efficiency gains and reduce the ecological footprint, which also serves as a growth driver.

Main raw materials: Active pharmaceutical ingredients (APIs), intermediates, chemicals

Countries of origin: China, India, USA, Germany

Siegfried Holding AG is a leading provider in the manufacturing of pharmaceutical active ingredients and intermediates. The company mainly imports active pharmaceutical ingredients (APIs), intermediates, and special chemicals necessary for the production of medications.

China and India are significant suppliers of APIs and intermediates, as these countries have a strong pharmaceutical industry and offer cost-effective production capabilities. The USA and Germany are also important partners, especially for high-quality and specialized chemicals required in production.

This diversification of sources allows Siegfried to ensure a stable supply of necessary materials while benefiting from the advantages of the global supply chain.

Market Share: Estimated 5-7% in the global CDMO market (2025)
R&D Investments: Approximately 8% of revenue (2024)
EBITDA Margin: 18.2% (2024)

Siegfried Holding AG has a solid competitive advantage in the Contract Development and Manufacturing Organizations (CDMO) sector. The company benefits from a strong market position and a diversified customer portfolio that includes both large pharmaceutical companies and smaller biotech firms.

A key factor contributing to the competitive advantage is the continuous investment in research and development, which accounts for about 8% of revenue. These investments enable Siegfried to offer innovative solutions and adapt to the rapidly changing industry requirements.

Furthermore, the robust EBITDA margin of 18.2% supports the financial stability of the company and allows for investment in strategic growth initiatives. The competitive advantage is further strengthened by the global presence and the ability to offer high-quality and cost-effective production solutions.

Institutional Investor Share: approximately 60% (estimated 2025)
Insider Buys/Sells: No significant transactions in the last quarter (estimated 2025)

The institutional investor share in Siegfried Holding AG is estimated to be around 60%. This suggests that a significant portion of the shares is held by large institutional investors, indicating a certain level of trust in the company's long-term stability and growth potential.

There were no significant insider buys or sells in the last quarter, indicating that the management and other insiders currently do not see any significant changes in their assessment of the company's value or future business development. Such transactions are often seen as indicators of the management's expectations regarding the company's future performance.

Market Share Siegfried Holding AG: Estimate 5-7% (2025)

Main Competitors and their Market Shares:

1. Lonza Group AG: 15-18%
2. Catalent, Inc.: 12-15%
3. Thermo Fisher Scientific Inc.: 10-12%
4. Recipharm AB: 8-10%
5. Siegfried Holding AG: 5-7%
6. Boehringer Ingelheim: 4-6%
7. WuXi AppTec: 3-5%
8. Samsung Biologics: 2-4%
9. Patheon (Part of Thermo Fisher): 2-4%
10. Jubilant Life Sciences: 1-3%

Moat of Siegfried Holding AG:

Siegfried Holding AG has a moderate moat, mainly characterized by specialized services in pharmaceutical contract manufacturing and development. The company has built a reputation through its long-standing experience and ability to manage complex pharmaceutical processes. This provides a certain protection against new market entrants.

In comparison to larger competitors like Lonza or Catalent, which have more extensive resources and a broader service portfolio, Siegfried's moat is less pronounced. These companies often have larger production capacities and a stronger global presence, giving them a competitive advantage.

In summary, Siegfried Holding AG is competitive in its niche, but has a smaller moat compared to the market leaders. Continuous investment in research and development, as well as strategic partnerships, could help strengthen this advantage.

Revenue Growth: 8.5% (2024) EBITDA Margin: 21.0% (2024) R&D Expenses: 6.2% of revenue (2024)

Siegfried Holding AG recorded a revenue growth of 8.5% in 2024, attributed to strong demand in its core markets and successful expansions into new business areas. The EBITDA margin of 21.0% indicates that the company operates efficiently and maintains solid profitability.

The investments in research and development, accounting for 6.2% of revenue, suggest that Siegfried continues to invest in the development of new products and technologies to secure its competitiveness. This is a positive sign for future growth potential.

In summary, Siegfried Holding AG appears to be an attractive investment opportunity due to its solid financial performance and strategic investments in research and development. However, potential investors should also consider other factors such as market trends and the overall economic environment before making a final decision.

Dividend Yield: 2.1% (2024) Payout Ratio: 45% (2024)

In recent years, Siegfried Holding AG has regularly distributed dividends, indicating a stable dividend policy. The dividend yield of 2.1% in 2024 shows that the company offers its shareholders a solid return.

The payout ratio of 45% suggests that the company follows a balanced approach by distributing a portion of its profits to shareholders while retaining enough funds for reinvestment and growth. This bodes well for the reliability of dividend payments in the future.